Ibex Medical Analytics & Institut Curie (Curie Cancer Carnot Institute) partner to improve AI-powered breast cancer detection

<p> Institut Curie (Curie Cancer Carnot Insitute) and Ibex Medical Analytics, a pioneer in artificial intelligence based cancer diagnostics, announce a research partnership aimed at improving diagnosis of breast cancer with Artificial Intelligence</p> <p> This research partnership, the first of its kind, will include a rich dataset of breast biopsy slides, digitized using a digital pathology scanner and analyzed for cancer detection by Ibex’s Galen™ Breast solution. Independently, multiple pathologists from Institut Curie (Curie Cancer Carnot Insitute) will diagnose the slides, followed by blinded analysis of the AI-solution’s performance. Galen Breast - the first AI solution used for detection of breast cancer in pathology - was developed utilizing state-of-the-art AI and machine learning techniques and trained on hundreds of thousands of image samples.</p> <p> This partnership is, once again, indicative of Institut Curie's partnership strategy, as outlines Amaury Martin, PhD, head of Technology Transfer Office at Institut Curie and head of Carnot Curie Cancer: <br /><em>"This collaboration illustrates Institut Curie's approach to partnership-based research, combining the expertise of clinicians with the know-how of an innovation-driven technology company. It illustrates our commitment to play a major role in the development of artificial intelligence approaches applied to personalized medicine."</em><br />  </p>